VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
UPC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
UPCUniverse Pharmaceuticals Inc.
$4.69$3M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksUPCP/E History

UPC logoUniverse Pharmaceuticals Inc. (UPC) P/E Ratio History

Deep Value

Trading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2022

Current P/E (TTM)
-0.0x
-100% vs 5Y avg
5Y Avg P/E
2.9x
Median 3.0x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-0.0x
Min1.5xMedian3.0xMax4.4x
TTM EPS$-22.01
Price$4.69
Earnings YieldN/A
EPS Growth (1Y)26.5%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, Universe Pharmaceuticals Inc. (UPC) trades at a price-to-earnings ratio of -0.0x, with a stock price of $4.69 and trailing twelve-month earnings per share of $-22.01.

The current P/E is 100% below its 5-year average of 2.9x. Over the past five years, UPC's P/E has ranged from a low of 1.5x to a high of 4.4x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, UPC trades at a 100% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

Relative to the broader market, UPC trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our UPC DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

UPC Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-0.0vs23.7
-100%
Below Sector
vs. S&P 500
-0.0vs25.3
-100%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 26% EPS growth (1Y)

UPC P/E vs Peers

Traditional Chinese medicine producers peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
CPRX logoCPRXCatalyst Pharmaceuticals, Inc.
$4B18.71.00Best+28%
SIGA logoSIGASIGA Technologies, Inc.
$227M9.6Lowest--60%
MCK logoMCKMcKesson Corporation
$105B22.9-+49%
CAH logoCAHCardinal Health, Inc.
$52B30.6-+325%Best
HSIC logoHSICHenry Schein, Inc.
$10B26.08.25+7%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

UPC Historical P/E Data (2021–2022)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2022 Q4Sep 30 2022$2034.00$672.153.0x+6%
FY2022 Q2-$4554.00$3087.401.5x-49%
FY2021 Q4-$8892.00$3442.882.6x-10%
FY2021 Q2Mar 31 2021$14436.00$3298.774.4x+53%

Average P/E for displayed period: 2.9x

Export Data
Consensus & Technical Research Suite
Open UPC Terminal

UPC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

5+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

UPC — Frequently Asked Questions

Quick answers to the most common questions about buying UPC stock.

What is UPC's P/E ratio?

Universe Pharmaceuticals Inc. (UPC) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-22.01. The 5-year average P/E is 2.9x and the historical range spans 1.5x to 4.4x.

Is UPC stock overvalued or undervalued?

UPC current P/E: -0.0x. 5-year average P/E: 2.9x. Percentile: 0th.

Is UPC stock expensive?

UPC is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 2.9x (0th percentile of historical range).

What is UPC's historical P/E range?

Over the past 5 years, UPC's P/E ratio has ranged from 1.5x to 4.4x, with a median of 3.0x and an average of 2.9x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2021–2022.

How does UPC's P/E compare to the S&P 500?

UPC current P/E: -0.0x. S&P 500 median P/E: 25.3x.

How does UPC's valuation compare to Healthcare peers?

Universe Pharmaceuticals Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.

What is UPC's PEG ratio?

UPC PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 26.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is UPC's earnings yield?

UPC earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

UPC P/E Ratio History (2021–2022)

Quarterly valuation multiple from closing price and trailing EPS

Current3.0x
Period Avg2.9x
Range1.5x - 4.4x
Change-31%
4 quartersMar 31, 2021 - Sep 30, 2022